The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac
12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD) [clinicaltrials:NCT00144196]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac
Bio2RDF identifier
929b08f11e43827c9a7d3d2a023da9ac
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac
measure [clinicaltrials_vocabulary:measure]
The primary efficacy endpoint ...... weeks of randomised treatment.
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac
title
The primary efficacy endpoint ...... randomised treatment. week 12
@en
inDataset
type
label
The primary efficacy endpoint ...... b08f11e43827c9a7d3d2a023da9ac]
@en